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ABSTRACT
Background: Beyond their role in hemostasis and thrombosis, platelets are important for modulating inflam-
matory reactions. Activated platelets play a role in the pathomechanism of inflammatory diseases such as
asthma, but little is known about platelet activation in chronic skin inflammation, including atopic dermatitis (AD)
and psoriasis. Furthermore, the relationship between platelet activation and disease severity is not understood.
This work was performed to investigate plasma levels of β-thromboglobulin (β-TG) and platelet factor 4 (PF4)
as platelet activation markers in patients with AD or psoriasis, and to determine the relationships between
these markers and disease severity.
Methods: Plasma levels of β-TG and PF4 were measured by enzyme-linked immunoassay in 22 healthy con-
trols, 44 patients with AD, and 16 patients with psoriasis. The relationships between these markers and the
scoring AD (SCORAD) index, blood eosinophilia, serum IgE and serum lactate dehydrogenase were investi-
gated in AD patients, and relationships with the psoriasis area and severity index (PASI) score were examined
in psoriatic patients.
Results: Plasma β-TG and PF4 levels were significantly higher in patients with AD or psoriasis compared with
healthy controls. β-TG and PF4 levels correlated with the SCORAD index, and PF4 levels correlated with PASI
scores. Elevated β-TG and PF4 levels were significantly reduced after treatments.
Conclusions: Our results show that blood platelets are activated in patients with AD or psoriasis, suggesting
that activated platelets play a role in the pathomechanism of chronic skin inflammation. Furthermore, plasma β-
TG and PF4 may be markers for the severity of AD and psoriasis.
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INTRODUCTION
The role of platelets in inflammatory processes is in-
creasingly being recognized, in addition to their func-
tion in hemostasis and thrombosis.1-11 Following acti-
vation, platelets rapidly release mediators stored in
dense or α-granules, including adenosine diphos-
phate, adenosine triphosphate, serotonin, cytokines
and chemokines, and these molecules may affect in-
duction and maintenance of allergic inflammatory re-
actions.1 Indeed, involvement of platelets has been
demonstrated in pathomechanisms of inflammatory
disorders including asthma,2-6 arthritis7 and inflam-
matory bowel disease.8-10 The best known platelet
chemokines are β-thromboglobulin (β-TG) and plate-
let factor 4 (PF4), which are released from α-granules
following activation of platelets12,13 and are therefore
considered to be platelet activation markers.
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Atopic dermatitis (AD) and psoriasis are typical
chronic inflammatory diseases of the skin. AD is fre-
quently associated with high serum IgE levels, posi-
tive immediate-type hypersensitivity to environmental
allergens, and eosinophilia.14 Th2-dominant immune
responses to allergens in the skin based on undefined
genetic predispositions are the central feature of
AD,15 and scratching due to severe itch often results
in excoriation and subsequent platelet aggregation at
the inflamed lesion. The plasma levels of β-TG and
PF4 are increased in patients with AD,16 but the rela-
tionship between platelet activation and disease se-
verity has not been examined.
Psoriasis is a chronic relapsing inflammatory dis-
ease characterized by scaly, red cutaneous plaques.
Epidemiological studies have shown that psoriasis
represents a risk factor for thrombotic vascular dis-
eases.17,18 In a large retrospective case-controlled
study, the incidences of myocardial infarction, cere-
brovascular accidents, thrombophlebitis and pulmo-
nary embolism were significantly higher in psoriatic
patients than in non-psoriatic dermatological pa-
tients.17 Several studies have suggested platelet acti-
vation in psoriatic patients,19-23 and Ludwig et al.
showed increased platelet P-selectin expression in pa-
tients with psoriasis19 and a correlation between P-
selectin expression levels in platelets and disease se-
verity measured by the psoriasis area and severity in-
dex (PASI).19 These findings suggest that platelets
play a role in psoriasis, but little is known about plate-
let chemokines in patients with psoriasis. In the cur-
rent study, we evaluated platelet activity based on
plasma β-TG and PF4 levels in patients with AD or
psoriasis, and investigated the relationships between
these markers and disease severity.
METHODS
SUBJECTS
Forty-four patients (21 men and 23 women) with AD
were enrolled in the study. Diagnosis of AD was
based on the criteria of Hanifin and Rajka.24 The aver-
age age of AD patients was 29.4 years (range: 17―52
years of age) . The clinical severity of AD was deter-
mined using the scoring AD (SCORAD) index25 (me-
dian score: 43.2; range: 24.5―59.8). Peripheral eosino-
phil count (median: 637.3; range: 300―1600 μl), se-
rum total IgE (median: 16048.3; range: 839―87200
IUml), and serum lactate dehydrogenase (median:
275.3; range: 155―550 IUl) were also examined.
Each patient had a history of AD for more than three
years, but none had received topical steroids or oral
medications during the two weeks preceding the
study.
Sixteen patients (11 men and 5 women) with pso-
riasis were also included in the study. Eligible pa-
tients had been diagnosed with plaque psoriasis for at
least 6 months with at least 10% of total body surface
area affected. The average age of the patients was
48.2 years (range: 28―78 years of age). Severity of
psoriasis was assessed using the PASI score26 (me-
dian score: 15.8; range: 12.2―18.7). None of the pa-
tients had received topical or oral medication during
the two weeks preceding the study.
The control group consisted of 22 healthy subjects
(10 men and 12 women; average age: 30.2 years;
range: 24―43 years). The control subjects did not take
any medication for at least two weeks preceding the
study.
The serum creatinine concentration was normal in
all subjects, which is of significance since clearance
of β-TG is impaired in renal insufficiency.27 Individu-
als were excluded from the study if their history indi-
cated disorders affecting platelet activity, such as obe-
sity, hypertension, dyslipidemia or diabetes. None of
the patients or controls were smokers. All subjects
gave written consent, and the study was approved by
the Kyoto Prefectural University ethics committee
and conducted in accordance with the Declaration of
Helsinki.
MEASUREMENT OF β-TG AND PF4 IN BLOOD
SAMPLES
To minimize platelet activation during sample collec-
tion, blood was drawn from antecubital veins through
20-gauge needles and mixed with 110 the volume of
acid citrate dextrose. The blood was then centrifuged
at 2500 × g for 20 minutes at 4℃, and the top third of
the resultant plasma supernatant was collected and
frozen at −80℃ for evaluation. Plasma levels of β-TG
and PF4 were measured by enzyme-linked immuno-
sorbent assay kits for quantitative detection of β-TG
(Diagnostica Stago, Asnieres, France) and PF4 (R&D
Systems, Minneapolis, MN) according to the manu-
facturers’ instructions.
STATISTICAL ANALYSIS
Data are expressed as medians ± SD, and compari-
sons between groups were performed by the Mann-
Whitney U-test. Correlation coefficients were ob-
tained by Spearman tests. P values lower than 0.05
were considered to be significant.
RESULTS
CONCENTRATIONS OF β-TG AND PF4
Plasma β-TG and PF4 levels in patients with AD or
psoriasis and in healthy controls are shown in Figure
1. Both β-TG and PF4 in patients with AD were sig-
nificantly higher than in controls, and there was also
a significant increase in β-TG and PF4 in patients with
psoriasis compared with controls. Plasma levels of β-
TG and PF4 did not differ significantly between pa-
tients with AD and those with psoriasis.
RELATIONSHIPS OF β-TG AND PF4 WITH DIS-
EASE SEVERITY IN AD PATIENTS
Plasma levels of β-TG and PF4 were correlated with
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Fig. 1 Plasma levels of β-TG and PF4 in patients with AD and psoriasis and in 
healthy controls. The plasma levels of β-TG and PF4 in patients with AD or psoria-
sis were significantly higher than those in the healthy controls. 
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Fig. 2 Relationships between plasma levels of β-TG or PF4 and the SCORAD index 
in patients with AD. Plasma β-TG and PF4 levels were corelated with the SCORAD 
index.
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the SCORAD index (Fig. 2). However, there was no
relationship between plasma β-TG levels and periph-
eral eosinophil count (r = 0.28, P = 0.17), serum total
IgE (r = 0.24, P = 0.11) and serum LDH (r = 0.05, P =
0.75), and no correlation was found between plasma
PF4 levels and peripheral eosinophil count (r = 0.22,
P = 0.16), serum total IgE (r = 0.27, P = 0.08) and se-
rum LDH (r = 0.09, P = 0.58).
RELATIONSHIPS OF β-TG AND PF4 WITH DIS-
EASE SEVERITY IN PSORIASIS PATIENTS
Plasma PF4 levels were correlated with severity of
psoriasis measured by the PASI score, but plasma β-
TG levels were not related to the PASI score (Fig. 3).
CHANGES IN β-TG AND PF4 LEVELS BEFORE
AND AFTER TREATMENTS
The β-TG and PF4 levels were determined in patients
with AD and psoriasis before and after treatments.
Patients had been treated with conventional therapy
such as topical steroids. Paired samples were ob-
tained from 6 AD patients and 3 psoriatic patients.
Elevated β-TG and PF4 levels were significantly re-
duced after treatments in patients with AD (Fig. 4A)
and psoriasis (Fig. 4B).
PLATELET COUNTS
There was no significant difference in peripheral
platelet count between healthy controls (median:
220.3 × 103; range: 159―296×103μl) and patients with
AD (median: 269.2 × 103; range: 194―365 × 103μl) or
psoriasis (median: 215.6 × 103; range:138―315 × 103 
μl).
DISCUSSION
The results of the study show that blood platelets are
activated in patients with AD and psoriasis, and dem-
onstrate for the first time that plasma levels of β-TG
and PF4 are correlated with the SCORAD index in pa-
tients with AD, and plasma PF4 levels are also corre-
lated with PASI scores in patients with psoriasis. In
addition, elevated β-TG and PF4 levels were signifi-
cantly reduced after treatments. These findings sug-
gest that activated platelets may play a role in the
Tamagawa-Mineoka R et al.
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Fig. 3 Relationships between plasma levels of β-TG or PF4 and PASI score in pa-
tients with psoriasis. Plasma PF4 levels were corelated with the PASI score, but there 
was no relationship between plasma β-TG levels and the PASI score.
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Fig. 4 Changes in plasma β-TG and PF4 levels before and after treatments. 
Paired samples were obtained from 6 AD patients and 3 psoriatic patients. Ele-
vated β-TG and PF4 levels were significantly reduced after treatments in patients 
with AD (A) and psoriasis (B). ＊P＜0.05.
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pathomechanism of chronic skin inflammation. We
have recently shown that platelets have an important
role in leukocyte recruitment of chronic skin inflam-
mation in a murine model of chronic dermatitis,
through formation of platelet-leukocyte aggregates
via P-selectin in peripheral blood and secretion of
chemokines at inflamed sites.28 Platelets have also
been shown to be important in the development of cu-
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taneous inflammation through direct activation of lo-
cal vascular capillary endothelial cells and attraction
of effector T cells into the tissue.29,30 Platelets contain
various chemokines including β-TG and PF4, which
attract and stimulate leukocytes and further activate
other platelets.31 Interestingly, β-TG and PF4 are in-
creased in inflammatory skin diseases and in other in-
flammatory diseases; for example, β-TG and PF4 are
elevated in bronchoalveolar lavage fluid during the
late inflammatory response after allergen challenge in
asthmatics, and are increased in the peripheral blood
in patients with inflammatory bowel disease.10
In allergic skin inflammation such as AD, it has
been shown that platelet-derived soluble factors in-
cluding β-TG and PF4 may be important for leuko-
cyte recruitment to skin.28 In AD, an elevated number
of eosinophils in peripheral blood and inflamed sites
is a characteristic feature.32 Eosinophils from the
blood of AD patients show a potentiated migratory re-
sponse to PF4 compared with eosinophils from nor-
mal controls.33 Moreover, PF4 not only modulates
the chemotactic activity of eosinophils, but also in-
creases eosinophil adhesion.34 It has been also re-
ported that gene expression of PF4 is elevated in a
mouse model of AD.35 Therefore, the platelet-derived
chemokines such as PF4 may be related to recruit-
ment and activation of leukocytes in AD. In psoriatic
patients, the characteristic features of involved skin
are epidermal proliferation and neutrophil infiltration.
The specific factors contributing to keratinocyte pro-
liferation have yet to be identified clearly, but acti-
vated platelets secrete mitogenic factors that stimu-
late proliferation in several cell lines,36 and therefore
may be involved in epidermal proliferation in psoria-
sis. In addition, platelets affect neutrophil activation
by release of many mediators, including PF4,
thromboxane A2, and platelet-derived growth factor,31
which may lead to neutrophil infiltration in psoriasis.
The precise mechanism through which circulating
platelets are activated in chronic skin inflammation
remains to be elucidated. Platelet hyperaggregation
in psoriatic patients has been shown20 and might be
related to alterations in arachidonic acid metabolism
in platelets22; however, the function of platelet aggre-
gation is not impaired in AD patients.37 The high and
low affinity receptor for IgE is expressed on the sur-
face of human platelets,38,39 suggesting that stimula-
tion of platelets by IgE may induce platelet activation
in AD. Endothelial cells activated by proinflammatory
cytokines and chemokines such as platelet-activating
factor released during skin inflammation may also be
involved.40,41 Therefore, activation of the immune sys-
tem may cause various proinflammatory mediators to
induce concomitant activation of platelets.
In conclusion, our results indicate that blood plate-
lets are activated in patients with AD and psoriasis.
Plasma levels of β-TG and PF4 were correlated with
the SCORAD index in patients with AD, and plasma
PF4 levels were also correlated with the PASI score
in patients with psoriasis. In addition, elevated β-TG
and PF4 levels were significantly reduced after treat-
ments. These findings suggest that activated platelets
may play an important role in the pathomechanism of
chronic skin inflammation, and that β-TG or PF4 may
be a marker for the severity of chronic skin inflamma-
tion such as AD or psoriasis. However, platelet activ-
ity as expressed by the β-TG or PF4 level was not cor-
related with other factors related to disease severity.
This observation requires further investigation in a
larger group of patients with AD or psoriasis.
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